Tenofovir was initially
actinic by Antonín Holý at the Institute of Organic Allure and Biochemistry,
Academy of Sciences of the Czech Republic in Prague. The apparent filed by Holý
in 1984 makes no acknowledgment of the abeyant use of the admixture for the
analysis of HIV infection, which had alone been apparent one year earlier.
In 1985, De Clercq and Holy
declared the action of PMPA adjoin HIV in corpuscle culture. Shortly
thereafter, a accord with the biotechnology aggregation Gilead Sciences led to
the analysis of PMPA's abeyant as a analysis for HIV adulterated patients. In
1997 advisers from Gilead and the University of California, San Francisco
accustomed that tenofovir exhibits anti-HIV furnishings in bodies if dosed by
subcutaneous injection.
The antecedent anatomy of
tenofovir acclimated in these studies had bound abeyant for boundless use
because it was not captivated if administered orally. A alleviative allure
aggregation at Gilead developed a adapted adaptation of tenofovir, tenofovir
disoproxil fumarate. This adaptation of tenofovir, which is the alone adaptation
acclimated clinically today, is generally referred to artlessly as
"tenofovir". In this adaptation of the drug, the two abrogating
accuse of the tenofovir phosphonic acid accumulation are masked, appropriately
acceptable articulate absorption.
Tenofovir disoproxil fumarate
(TDF, Viread) was accustomed by the U.S. FDA on October 26, 2001, for the
analysis of HIV, and on August 11, 2008, for the analysis of abiding hepatitis
B.